Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
Key PointsCRISPR Therapeutics' only approved product may experience increased demand...
Nasdaq News: Markets
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
CRSP Stock Slips 3% Despite ‘Encouraging’ CTX310 Data — Morgan Stanley Says Investor Focus Is Further Ahead
Morgan Stanley expects investor focus to shift to readouts from the next part of the same trial in patients with severe hypertriglyceridemia due in the back half of the year and other second-half readouts.
Stocktwits
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
Zacks
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Zacks
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
Key PointsCRISPR Therapeutics grew revenue by 1,043% year over year in the second quarter...
Nasdaq News: Markets
Recursion, Novavax and Crispr Stocks Trending in Pre-MarketHere's Why
Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.read more...